Characterization of a mobilization-competent simian immunodeficiency virus (SIV) vector containing a ribozyme against SIV polymerase

被引:5
作者
Morris, KV
Grahn, RA
Looney, DJ
Pedersen, NC
机构
[1] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA
[2] Univ Calif Davis, Dept Populat Hlth & Reprod, Davis, CA 95616 USA
[3] Univ Calif Davis, Dept Vet Med & Epidemiol, Davis, CA 95616 USA
关键词
D O I
10.1099/vir.0.19106-0
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Exploitation of the intracellular virus machinery within infected cells to drive an anti-viral gene therapy vector may prove to be a feasible alternative to reducing viral loads or overall virus infectivity while propagating the spread of a therapeutic vector. Using a simian immunodeficiency virus (SIV)-based system, it was shown that the pre-existing retroviral biological machinery within SIV-infected cells can drive the expression of an anti-SIV pol ribozyme and mobilize the vector to transduce neighbouring cells. The anti-SIV pol ribozyme vector was derived from the SIV backbone and contained the 5'- and 3'LTR including transactivation-response, psi and Rev-responsive elements, thus requiring Tat and Rev and therefore limiting expression to SIV-infected cells. The data presented here show an early reduction in SIV p27 levels in the presence of the anti-SIV pol ribozyme, as well as successful mobilization (vector RNA constituted similar to 17 % of the total virus pool) and spread of the vector containing this ribozyme. These findings provide direct evidence that mobilization of an anti-retroviral SIV gene therapy vector is feasible in the SIV/macaque model.
引用
收藏
页码:1489 / 1496
页数:8
相关论文
共 37 条
[31]   THE COMPLETE NUCLEOTIDE-SEQUENCE OF A PATHOGENIC MOLECULAR CLONE OF SIMIAN IMMUNODEFICIENCY VIRUS [J].
REGIER, DA ;
DESROSIERS, RC .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1990, 6 (11) :1221-1231
[32]   Ribozyme therapy for HIV infection [J].
Rossi, JJ .
ADVANCED DRUG DELIVERY REVIEWS, 2000, 44 (01) :71-78
[33]   Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1 [J].
Shafer, RW ;
Vuitton, DA .
BIOMEDICINE & PHARMACOTHERAPY, 1999, 53 (02) :73-86
[34]  
SYKES PJ, 1992, BIOTECHNIQUES, V13, P444
[35]   Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infection [J].
Weinberger, LS ;
Schaffer, DV ;
Arkin, AP .
JOURNAL OF VIROLOGY, 2003, 77 (18) :10028-10036
[36]  
Wu X, 2001, Dev Biol (Basel), V106, P237
[37]   INTRACELLULAR IMMUNIZATION OF HUMAN FETAL CORD-BLOOD STEM PROGENITOR CELLS WITH A RIBOZYME AGAINST HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 [J].
YU, M ;
LEAVITT, MC ;
MARUYAMA, M ;
YAMADA, O ;
YOUNG, D ;
HO, AD ;
WONGSTAAL, F .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (03) :699-703